DermTech, Inc. (DMTK)
- Previous Close
0.5854 - Open
0.5854 - Bid 0.5665 x 200
- Ask 0.6371 x 100
- Day's Range
0.5801 - 0.6300 - 52 Week Range
0.5800 - 3.8980 - Volume
86,345 - Avg. Volume
292,693 - Market Cap (intraday)
20.881M - Beta (5Y Monthly) 2.56
- PE Ratio (TTM)
-- - EPS (TTM)
-3.0900 - Earnings Date May 2, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.04
DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.
www.dermtech.com206
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: DMTK
Performance Overview: DMTK
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DMTK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DMTK
Valuation Measures
Market Cap
20.88M
Enterprise Value
19.41M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.29
Price/Book (mrq)
0.37
Enterprise Value/Revenue
1.27
Enterprise Value/EBITDA
-0.20
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-37.82%
Return on Equity (ttm)
-106.46%
Revenue (ttm)
15.3M
Net Income Avi to Common (ttm)
-100.89M
Diluted EPS (ttm)
-3.0900
Balance Sheet and Cash Flow
Total Cash (mrq)
55.86M
Total Debt/Equity (mrq)
95.14%
Levered Free Cash Flow (ttm)
-37.31M